Health Condition 1: N189- Chronic kidney disease, unspecified
Conditions
Interventions
Intervention1: Enzobiotics: First group of Subjects will be instructed to take the Enzobiotics twice daily 5 minutes before major food through oral route of administration
Intervention2: Enzobiotics:
Sponsors
Nil
Eligibility
Inclusion criteria
Inclusion criteria: 1.Subjects aged between 18 - 80yrs 2.eGFR greater than 15 ml per min per 1.73 m2 3.Patient wanting to delay dialysis 4.Willing to come for regular follow-up visits 5.Able to give written informed consent
Exclusion criteria
Exclusion criteria: 1.Pregnant and lactation. 2.Autoimmune disease e.g. SLE/Vasculitis. 3.Subjects with hepatic impairment (SGOT or SGPT levels greater than 3 times the upper limit) 4.Active infection patients. 5.Subjects with uncontrolled cardiovascular events or acute coronary syndrome. 6.Patients who have been prescribed Synbiotics and Enzymes. 7.Subjects with any other severe systemic illness and in the opinion of the investigator would be non-compliant with the visit schedule or study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Assess safety and efficacy of Enzobiotics and alpha ketoanalogue in CKD patients 2. Retardation of CKD progression 3. slope of eGFR and uACR Timepoint: 180 days Trial, 365 days follow up | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in BUN, Creatinine, Haemoglobin, Phosphorous, Calcium, Potassium, Sodium, Serum Albumin, Urea, Total Protein, Triglycerides, Total cholesterol, HDL, LDL, Hospitalization during study period, CBC and in vitals Heart rate, Change in Proteinuria, UACR, Patient Reported outcome SF36Timepoint: Day 1, Day 90, Day 180 | — |
Countries
India
Contacts
Public ContactDr Nisith Kumar Mohanty
Apollo Hospitals
Outcome results
None listed